NVP-LCQ195 NEW
| Price | $40 | $98 | $148 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-26 |
Product Details
| Product Name: NVP-LCQ195 | CAS No.: 902156-99-4 |
| Purity: 99.36% | Supply Ability: 10g |
| Release date: 2025/10/26 |
Product Introduction
Bioactivity
| Name | NVP-LCQ195 |
| Description | NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM). |
| In vitro | NVP-LCQ195 induced cell cycle arrest and eventual apoptotic cell death of MM cells, even at sub-1 mol/l concentrations, spared non-malignant cells, and overcame the protection conferred to MM cells by stroma or cytokines of the bone marrow milieu. In MM cells, LCQ195 triggered decreased amplitude of transcriptional signatures associated with oncogenesis, drug resistance and stem cell renewal, including signatures of activation of key transcription factors for MM cells e.g. myc, HIF-1a, IRF4[1]. |
| In vivo | Bortezomib-treated MM patients whose tumours had high baseline expression of genes suppressed by LCQ195 had significantly shorter progression-free and overall survival than those with low levels of these transcripts in their MM cells[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (217.24 mM), Sonication is recommended. H2O : Insoluble |
| Keywords | NVP-LCQ-195 | NVP-LCQ195 | NVPLCQ195 | NVP-LCQ 195 | NVP LCQ195 | LCQ195 | LCQ 195 | Inhibitor | inhibit | Cyclin dependent kinase | CDK5 | CDK3 | CDK2 | CDK1 | CDK | AT-9311 | AT 9311 |
| Inhibitors Related | Ribociclib | Ro-3306 | Abemaciclib | Rafoxanide | AT7519 | Palbociclib monohydrochloride | CASIN | Palbociclib | GW 441756 | Sodium Oxamate | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $37.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-10-26 | |
| $2500.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $35.00/1kg |
VIP5Y
|
Shanghai UCHEM Inc.
|
2023-11-10 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY